NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis $1.29 -0.11 (-7.86%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.01 (+0.78%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Allogene Therapeutics Stock (NASDAQ:ALLO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allogene Therapeutics alerts:Sign Up Key Stats Today's Range$1.29▼$1.4050-Day Range$1.29▼$2.2352-Week Range$1.04▼$4.46Volume6.44 million shsAverage Volume5.84 million shsMarket Capitalization$445.68 millionP/E RatioN/ADividend YieldN/APrice Target$8.30Consensus RatingModerate Buy Company Overview Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing “off-the-shelf” allogeneic CAR T-cell therapies for cancer. Unlike autologous CAR T treatments, which are manufactured from an individual patient’s own T cells, Allogene’s products are made from T cells collected from healthy donors and engineered to recognize specific cancer targets. The company uses gene-editing and other technologies intended to support scalable manufacturing and potentially broaden patient access to cell therapy. Allogene’s pipeline has included investigational treatments for blood cancers and solid tumors. Its lead programs have included cemacabtagene ansemeteucel, also known as cema-cel, an anti-CD19 CAR T-cell therapy being studied in B-cell malignancies, and ALLO-316, an investigational CAR T-cell therapy targeting CD70 in renal cell carcinoma. The company has also advanced programs targeting multiple myeloma and other cancers, with development status subject to change as clinical studies progress. Founded in 2018, Allogene is headquartered in South San Francisco, California, and conducts research and clinical development activities through studies in the United States and other locations. The company was co-founded and is led by David Chang, who serves as president and chief executive officer. Its therapies remain investigational and are not approved for general commercial use unless specifically authorized by regulators.AI Generated. May Contain Errors. Read More Allogene Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreALLO MarketRank™: 3.64013704045 of 5 starsAllogene Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 353rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 2 strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAllogene Therapeutics has a consensus price target of $8.30, representing about 543.4% upside from its current price of $1.29.Amount of Analyst CoverageAllogene Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Allogene Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.54% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Allogene Therapeutics has recently decreased by 6.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.97 News SentimentAllogene Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Allogene Therapeutics this week, compared to 4 articles on an average week.Search Interest16 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows7 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,958.00 in company stock.Percentage Held by Insiders13.20% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLO Stock News HeadlinesBiorestorative Therapies (NASDAQ:BRTX) and Allogene Therapeutics (NASDAQ:ALLO) Head-To-Head ReviewOctober 6, 2026 | americanbankingnews.comComparing Generate Biomedicines (NASDAQ:GENB) & Allogene Therapeutics (NASDAQ:ALLO)October 4, 2026 | americanbankingnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 13 at 1:00 AM | Base Camp Trading (Ad)Critical Comparison: Allogene Therapeutics (NASDAQ:ALLO) versus CG Oncology (NASDAQ:CGON)October 2, 2026 | americanbankingnews.comAllogene CEO Zach Roberts is pushing to make CAR T-cell therapy more accessible: 'That's what gets me out of bed'September 10, 2026 | msn.comAllogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comAllogene: If MRD Holds, This Becomes A Completely Different CompanySeptember 7, 2026 | seekingalpha.comAllogene Chief Financial Officer Geoffrey Parker RetiringSeptember 4, 2026 | marketwatch.comSee More Headlines ALLO Stock Analysis - Frequently Asked Questions How have ALLO shares performed this year? Allogene Therapeutics' stock was trading at $1.37 on January 1st, 2026. Since then, ALLO stock has decreased by 5.8% and is now trading at $1.29. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04. The company earned $4.64 million during the quarter, compared to analysts' expectations of $0 million. Read the conference call transcript. When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $306 million in an initial public offering on Thursday, October 11th 2018. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Iovance Biotherapeutics (IOVA), Pfizer (PFE), NIO (NIO), Intel (INTC) and Micron Technology (MU). Company Calendar Last Earnings8/12/2026Today10/13/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ALLO's financial health is in the Yellow zone, according to TradeSmith. ALLO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALLO CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees152Year Founded2018Price Target and Rating Average Price Target for Allogene Therapeutics$8.30 High Price Target$14.00 Low Price Target$3.85 Potential Upside/Downside+543.4%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.89 million Net MarginsN/A Pretax Margin-3,710.63% Return on Equity-50.04% Return on Assets-36.74% Debt Debt-to-Equity RatioN/A Current Ratio10.72 Quick Ratio10.72 Sales & Book Value Annual Sales$20 thousand Price / Sales22,284.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book0.99Miscellaneous Outstanding Shares345,490,000Free Float299,886,000Market Cap$445.68 million OptionableOptionable Beta0.56 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ALLO) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
